Characteristic | No (%)* |
City | |
New Orleans | 111 (65) |
San Francisco | 61 (35) |
Age (y) | |
<35 | 27 (16) |
35–44 | 75 (45) |
45–54 | 57 (34) |
⩾55 | 8 (5) |
Sex | |
Female | 48 (28) |
Male | 123 (72) |
Ethnicity | |
African–American | 123 (72) |
Caucasian | 33 (19) |
Other | 16 (9) |
CD4+ T cell count (cells/μl) | |
> 200 | 36 (25) |
101–200 | 32 (22) |
51–100 | 23 (16) |
⩽50 | 55 (38) |
HIV RNA (copies/ml) | |
<75 | 9 (8) |
⩾75–<20 000 | 20 (17) |
⩾20 000–<100 000 | 32 (28) |
⩾100 000 | 54 (47) |
Prior PCP | 53 (31) |
PCP prophylaxis on admit | |
Co-trimoxazole | 51 (30) |
Other | 20 (12) |
Aetiology of pneumonia | |
Bacterial | 104 (60) |
Opportunistic† | 22 (13) |
Non-infectious‡ | 18 (10) |
Undiagnosed | 28 (16) |
*Up to 57 observations may be missing (as for HIV RNA), but percentages are calculated as a proportion of actual observations. Percentages may not total 100% due to rounding. †Includes fungal, mycobacterial and viral pneumonias. ‡Includes Kaposi’s sarcoma, lymphoma and other non-infectious pulmonary processes, such as chronic obstructive pulmonary disease exacerbations and pulmonary oedema. PCP, Pneumocystis pneumonia.